A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

6.4K views

⸱

DOI:

10.3791/56795

⸱

January 25th, 2018

 ,  ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

We have successfully generated two substrate-specific γ-secretase assays. Both cell-based assays presented here are designed to quantify γ-secretase enzymatic activities via the output of firefly luciferase reporters.

Abstract

We have developed a pair of cell-based reporter gene assays to quantitatively measure γ-secretase cleavage of distinct substrates. This manuscript describes procedures that may be used to monitor γ-secretase-mediated cleavage of either APP-C99 or Notch, using a Gal4 promoter-driven firefly luciferase reporter system. These assays were established by stably co-transfecting HEK293 cells with the Gal4-driven luciferase reporter gene and either the Gal4/VP16-tagged C-terminal fragment of APP (APP-C99; CG cells), or the Gal4/VP16-tagged Notch-ΔE (NΔE; NG cells). Using these reporter assays in parallel, we have demonstrated that an ErbB2 inhibitor, CL-387,785, can preferentially suppress γ-secretase cleavage of APP-C99 in CG cells, but not NΔE in NG cells. The differential responses exhibited by the CG and NG cells, when treated with CL-387,785, represent a preferred characteristic for γ-secretase modulators, and these responses are in stark contrast to the pan-inhibition of γ-secretase induced by DAPT. Our studies provide direct evidence that γ-secretase activities toward different substrates can be differentiated in a cellular context. These new assays may therefore be useful tools in drug discovery for improved AD therapies.

Introduction

Oligomeric forms of amyloid-β (Aβ) are believed to be the primary cause of neurodegeneration in the brains of patients suffering from Alzheimer's disease (AD)1. Aβ peptides are produced by the stepwise cleavage of amyloid precursor protein (APP), first by β-secretase and then by γ-secretase2. In the past decade, therapeutic approaches toward treatment of AD have focused on the prevention of Aβ production3. The majority of studies have focused on either the augmentation of α-secretase activity, which can preclude γ-secretase cleavage of APP and thereby de....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Measurement of Luciferase Reporter Signals, which Correspond to γ-Secretase Cleavage of APP-C99 or NΔE

NOTE: Please refer to the previous publications for detailed descriptions of the generation of CG and NG cells20,21.

  1. Seed NG or CG cells (20, 000 cells/well) onto 96-well microplates at a final volume of 200 μL/well in growth medium that is composed of Dulbecco's Modified Eagle Medium (DMEM) plus 10% fetal bovine serum (FBS), 5 μg/mL blasticidin, 250 μg/mL antibiotic (e.g., zeocin), and 200 μg/mL hygromycin B.

Access restricted. Please log in or start a trial to view this content.

Results

Inhibition of ErbB2 by CL-387,785 can differentially promote the processing of APP-C99 by γ-secretase without affecting Notch cleavage
To establish a cell-based assay that can quantitatively measure the proteolytic cleavage of a particular γ-secretase substrate, we generated the HEK293-derived CG cell line by stable co-transfection of a tetracycline-inducible C-terminally Gal4/VP16-tagged APP-C99 and a Gal4 promoter-driven firefly luc.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The promising outcomes from a phase 1b trial of aducanumab immunotherapy for AD have firmly established the critical role of Aβ in the pathogenesis of AD22 and suggest that anti-Aβ approaches are still a viable strategy for the development of anti-AD drugs. Here, we describe cell-based assays for quantifying γ-secretase-catalyzed proteolysis of APP-C99 and NΔE using firefly luciferase reporter systems. APP-C99 and NΔE are the two most well-studied γ-secretase substrat.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors thank the Core Facility of the Institute of Cellular and Organismic Biology, Academia Sinica, for technical support. This study was supported by the Ministry of Science and Technology, Taiwan (MOST 103-2320-B-001-016-MY3 to Y.-F. L.), the Program for Translational Innovation of Biopharmaceutical Development – Technology Supporting Platform Axis Scheme (NP7 to Y.-F.L.), and Academia Sinica (to Y.-F.L.).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
VictorLight luminescence plate readerPerkinElmer2030-0010
Class II, Type 2 Biological Safety CabinetThermo Scientific1300 Series A2
CL-387,785EMD Calbiochem233100-1MG
DAPTMerck565770
Dulbecco’s Modified Eagle Medium (DMEM)Thermo Fisher12100046main compnent of growth medium
Fetal bovine serum (FBS)Thermo Fisher16000044
BlasticidinThermo FisherA1113903
ZeocinThermo FisherR25005
Hygromycin BGibco10687010
HemocytomerSigma-AldrichBR717805 Aldrich
96-well microplateNunc156545
TetracyclineSigmaT7660
Dimethyl sulfoxide (DMSO)SigmaD2650
Steady-Glo luciferase assay reagentPromegaE2510
Humidified CO2 incubatorRevcoUltima II
T-REx293 cell lineInvitrogenR71007
Wallac 1420 software version 3.0PerkinElmerinstrument control software of the luminescence microplate reader

References

  1. Selkoe, D. J., Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 8 (6), 595-608 (2016).
  2. Wolfe, M. S., Guenette, S. Y. APP at a glance. J Cell Sci. 120 (Pt 18), 3157-3161 (2007).
  3. Karran, E., Mercken, M., De Strooper, B.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Gamma Secretase AssayAPP Cleavage MeasurementNotch Cleavage AnalysisLuciferase Reporter SystemHEK293 Cell CultureCL-387 785 TreatmentDAPT Inhibition StudySubstrate Selectivity AnalysisAlzheimer Disease ResearchDrug Discovery Platform